Ozempic Brain Fog: What the Labels, Trials and Reports Show

Brain fog is not a listed side effect of Ozempic, Wegovy, Mounjaro or Zepbound. None of the four FDA labels mentions memory, concentration or cognition in its adverse reactions.^[1][2] No trial has set out to measure it, and the medical literature on GLP-1 drugs and brain fog is close to empty. Trials that did test thinking skills on these drugs, in diabetes and in Alzheimer’s disease, found no harm and, for the most part, no benefit. What the labels do list are the things that reliably fog anyone: fatigue, dizziness, dehydration from vomiting or diarrhea, and hypoglycemia in people whose regimen also includes insulin or a sulfonylurea. Those are the first places to look.

What the four labels list, and what they leave out

A drug label’s adverse reactions section counts what happened more often on the drug than on placebo in the trials. Searching the full text of all four labels, the words “cognitive,” “memory” and “brain fog” do not appear anywhere. The word “confusion” appears once in each, and in every case it is in the patient leaflet’s list of low blood sugar symptoms.^[1][2][3]

Fatigue on Wegovy and Zepbound rises with the dose, which is the clearest sign the label gives that a drug effect is involved in how tired people feel. Fatigue is not the same as brain fog, but people often use the two words for one experience: slow, flat, hard to focus. Our fatigue article takes that dose pattern apart.

A label can only count what a trial recorded. Weight-loss trials collect side effects as patients report them; they do not run memory or attention tests on everyone. So the absence of brain fog from the labels means it did not stand out as a reported side effect in thousands of trial participants. It does not prove no individual ever experiences it.

Does Ozempic affect your brain?

Yes, by design. The appetite effect works through the brain, and the labels say so directly.

GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation.^[1]

— Wegovy prescribing information, section 12.1

The Zepbound label says the same of tirzepatide’s two receptors, and both labels describe animal studies in which the drug reached and switched on neurons in feeding-related brain regions.^[1][2] Acting on the brain’s appetite circuits is a different claim from impairing thinking, and no study has shown that it does the second. Whether the drug also touches reward and motivation is a live research question we cover in semaglutide and motivation.

What research has measured: thinking tests, not fog

The research gap is close to total. In PubMed, the US index of medical journals, a search pairing “brain fog” with semaglutide, tirzepatide, liraglutide or GLP-1 returns a single paper, and it is a review of long COVID that mentions GLP-1 drugs only as something future research might try.^[5] Paired with the brand names, the search returns nothing.

What does exist are randomized trials that tested cognition with standard tasks, mostly to see whether these drugs protect the brain. They are useful here for a different reason: had the drugs dulled thinking, these tests were built to pick it up.

Across more than 17,000 randomized participants, no trial reported thinking getting worse on the drug. The Alzheimer’s result and the earlier observational hopes are covered in the evoke result and GLP-1s and dementia risk; the depression trial in its own article.

Two limits keep this from being a clean all-clear. These trials enrolled older people with diabetes or dementia, not younger adults taking a GLP-1 for weight, and most used drugs or doses other than Wegovy 2.4 mg and Zepbound. And a standard cognitive test measures performance on a task. Brain fog is a feeling of effort and slowness that can exist while test scores stay normal. Absence of harm on the tests is real evidence; it is not evidence about the feeling.

What the adverse event reports show

FDA’s Adverse Event Reporting System collects voluntary reports from patients, doctors and manufacturers. “Brain fog” is one of its standard reporting terms, so the reports can be counted.

Brain fog appears in about 3 of every 1,000 semaglutide reports and about 2 of every 1,000 tirzepatide reports.^[10][11] Those are shares of reports, not of users. The reports are voluntary, nobody knows how many people took the drugs, and a report says only that a symptom followed the drug, not that the drug caused it. Publicity drives reporting too, and brain fog on Ozempic has been widely written about.

No published pharmacovigilance study has tested whether cognitive complaints are reported disproportionately often with these drugs compared with others. A 2026 review that weighed the neuropsychiatric evidence on GLP-1 and GIP/GLP-1 drugs against standard causation criteria, cognitive effects included, concluded the evidence “remains insufficient to establish causality” for most of the outcomes it examined.^[12]

The ordinary explanations, ranked by how well they are supported

What follows is inference. No study has taken people with brain fog on a GLP-1 and identified the cause. Each item is something the labels document as happening on these drugs, combined with separate evidence that it impairs thinking.

Hypoglycemia, for people on insulin or a sulfonylurea too

This one is on the label, word for word. Every GLP-1 leaflet lists confusion and drowsiness among the signs of low blood sugar, alongside shakiness, sweating, slurred speech and blurred vision.^[3][4] Wegovy’s label ties the extra hypoglycemia risk to pairing it with insulin, or with drugs that force insulin release, sulfonylureas being the common example.^[1] On a GLP-1 alone, without those drugs, it is uncommon. Fog that arrives a few hours after a meal, or with sweating and shakiness, is worth a glucose check. More in GLP-1s and low blood sugar.

Dehydration

Nausea, vomiting and diarrhea are the commonest side effects on all four labels, and each label has a kidney warning because those fluid losses can be large enough to cause acute kidney injury, especially when starting or raising the dose.^[1][2] Separately, a meta-analysis of 33 experiments found that dehydration measurably impairs attention and executive function, with larger effects once fluid loss passes about 2% of body weight.^[13]

Eating too little

Large drops in food intake are the point of the drug and can overshoot. Running short on energy, iron or vitamin D is plausible as a contributor to sluggish thinking, but here the link to brain fog specifically is reasoning, not measurement. The intake data are in eating too little on a GLP-1, which also covers the rare but serious thiamine deficiency that can follow weeks of vomiting.

Poor sleep and fatigue

Lost sleep impairs working memory and mental flexibility; a 2025 meta-analysis of 79 studies found damage across every core executive function it measured.^[14] Nausea at night, reflux and early-morning hunger can all cut into sleep on these drugs. On the other side, one uncontrolled study reported sleep quality improving after starting treatment, covered in GLP-1s, sleep quality and mood, and a cohort study found a small rise in daytime sleepiness diagnoses, in GLP-1s and daytime sleepiness.

Mood

Low mood and anxiety both impair concentration, and both have been reported in people on these drugs. Anxiety on a GLP-1, and how thin the evidence on it is, gets its own companion piece: GLP-1s and anxiety.

Matching the pattern to the likely cause

When it is not brain fog: get help the same day

• Confusion, slurred speech or drowsiness in someone taking insulin or a sulfonylurea. Check blood sugar right away and follow the low blood sugar plan you were given; call 911 if they cannot swallow or stay awake.^[4]
• Confusion with vomiting that will not stop, or an inability to keep fluids down. That is dehydration severe enough to threaten the kidneys.^[2]
• Confusion, double vision or unsteady walking after weeks of vomiting or barely eating. This can be thiamine deficiency, an emergency covered in eating too little on a GLP-1.
• Any sudden change in thinking, speech, vision or strength on one side of the body. Call 911. A new medicine does not explain a sudden neurological change, and assuming it does wastes time.

Fog that is gradual, mild and steady is a reason for a routine appointment rather than an emergency. Bring a list of everything you take, your dose history and what you are eating. If the fog started within days of a dose increase, say so; that timing is the most useful single fact a prescriber can have.